The Chemotherapy Board provides guidance, oversight and support for the continuing development of chemotherapy services in the UK.
It was established in 2013 by The Royal College of Radiologists (RCR), the Royal College of Physicians (RCP), the Association of Cancer Physicians (ACP), the Royal College of Pathologists (RCPath), the British Oncology Pharmacy Association (BOPA) and the UK Oncology Nursing Society (UKONS). It has representation from across the four UK nations and from other organisations closely involved in chemotherapy services.
The Board’s strategic role includes:
- Co-ordinating work at national level to support commissioning and delivery of services locally
- Advising on the development and delivery of safe, high-quality chemotherapy services
- Working collaboratively with other groups and organisations across the UK involved in the delivery of chemotherapy services, including the Chemotherapy Clinical Reference Group and the Joint Collegiate Council for Oncology.
The Board's forward work programme includes:
- Contributing stakeholder views to the Chemotherapy Clinical Reference Group in its development of commissioning policies
- Developing a strategy and structure for workforce planning and training
- Supporting and encouraging the development of data sources to evaluate chemotherapy service provision
- Developing professional guidance and standards for chemotherapy service delivery
- Supporting and encouraging research in chemotherapy, by working collaboratively with the research community.
On 6 December 2018 the UK Chemotherapy Board hosted for the first time the annual Commissioning Chemotherapy Services conference. A full report from this event will be available in due course.